Enhanced IFNα Signaling Promotes Ligand-Independent Activation of ERα to Promote Aromatase Inhibitor Resistance in Breast Cancer
Aromatase inhibitors (AIs) reduce estrogen levels up to 98% as the standard practice to treat postmenopausal women with estrogen receptor-positive (ER+) breast cancer. However, approximately 30% of ER+ breast cancers develop resistance to treatment. Enhanced interferon-alpha (IFNα) signaling is upre...
Main Authors: | Taylor E. Escher, Prasad Dandawate, Afreen Sayed, Christy R. Hagan, Shrikant Anant, Joan Lewis-Wambi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/20/5130 |
Similar Items
-
AROMATASE INHIBITORS IN BREAST CANCER THERAPY
by: Hande Karahan, et al.
Published: (2011-04-01) -
Immunofluorescent Evidence for Nuclear Localization of Aromatase in Astrocytes in the Rat Central Nervous System
by: Diána Kata, et al.
Published: (2022-08-01) -
Melatonin as an Oncostatic Molecule Based on Its Anti-Aromatase Role in Breast Cancer
by: Yunho Jin, et al.
Published: (2021-01-01) -
Effect of β-agonist on the dexamethasone-induced expression of aromatase by the human monocyte cells
by: Masatada Watanabe, et al.
Published: (2017-02-01) -
Aromatase enzyme: Paving the way for exploring aromatization for cardio-renal protection
by: Manar A. Eissa, et al.
Published: (2023-12-01)